Roche Advances In HCV Protease Inhibitor Contest
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss pharma will move ITMN-191 into Phase II studies, triggering a $15 million milestone to InterMune.
You may also be interested in...
Market Likes Telaprevir For Twice-daily Dosing
Positive assessment follows market uncertainty as Vertex issues incorrect data, then makes correction.
Market Likes Telaprevir For Twice-daily Dosing
Positive assessment follows market uncertainty as Vertex issues incorrect data, then makes correction.
Vertex To Launch Phase III Trial Of Telaprevir In Treatment-failure HCV Patients
Biotech gets U.S. and EU approval to test HCV drug in full range of patients who failed in prior treatment.